ARTICLE | Discovery & Translation
Armgo molecule prevents cardiogenic dementia; Ten63’s improved HIV-1 Abs and more
BioCentury’s roundup of translational innovations
July 15, 2023 12:10 AM UTC
Columbia University scientists and collaborators found leaky RyR2 channels in hippocampal neurons from individuals with heart failure and showed in Nature Neuroscience that small molecule stabilization of the channels in mice prevented cognitive impairment induced by heart failure.
Author Andrew Marks founded Armgo Pharma Inc., which is developing molecules that bind to leaky ryanodine receptor channels to restore their function. The company raised $35 million in series B financing in December 2021 for a Phase II clinical trial of ARM210 to treat catecholaminergic polymorphic ventricular tachycardia...